<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953326</url>
  </required_header>
  <id_info>
    <org_study_id>00011271</org_study_id>
    <nct_id>NCT03953326</nct_id>
  </id_info>
  <brief_title>HeartPhone Cancer Survivors Trial 2019</brief_title>
  <official_title>Digital Intervention to Promote Physical Activity and Improve Cardiovascular Health Among Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a behavioral study that will examine changes in physical activity and vascular health
      in response to a digital tool (app) that will appear on participant's lock screen of their
      Android phone. Participants will be asked to use this app for 3 months and to wear a Fitbit
      device continuously throughout the study. Participants will be asked to complete
      questionnaires, participate in fitness testing and measures of cardiovascular health at 3
      months and 6 months after baseline assessments. The hypothesis is that exposure to the app
      will lead to increased physical activity volume and improved microvessel function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-group pre-post change</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical activity volume</measure>
    <time_frame>3 month</time_frame>
    <description>Daily step counts over 1-week from Fitbit device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microvessel function</measure>
    <time_frame>3 month</time_frame>
    <description>Skin blood flow during perfusion of endothelium-dependent and independent agonists</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>HeartPhone Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants install the HeartPhone app on their smartphone. This app presents an image on a splash screen every time they activate their device. The image is randomly drawn from an image bank in the app. Repeated exposure to the image is designed to condition a more favorable automatic affective evaluation of physical activity and lead to increased physical activity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>HeartPhone app</intervention_name>
    <description>Evaluative conditioning (temporally distributed micro-doses presented upon activation of smartphone screen)</description>
    <arm_group_label>HeartPhone Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylcholine</intervention_name>
    <description>Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter</description>
    <arm_group_label>HeartPhone Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitroprusside</intervention_name>
    <description>Endothelium-independent vasodilation is tested with the localized delivery of the nitric oxide donor</description>
    <arm_group_label>HeartPhone Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester</intervention_name>
    <description>This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.</description>
    <arm_group_label>HeartPhone Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years

          -  Diagnosis of breast cancer, leukemia, or lymphoma &lt;15 yrs

          -  Completed chemotherapy with cardiotoxic anthracycline-based agents 1+ year ago

          -  English-proficiency

          -  Own &amp; use smartphone with Android operating system

        Main Study and Ancillary Study Exclusion Criteria:

          -  Currently receiving curative treatment for cancer

          -  90+ min/week moderate (or greater) intensity PA

          -  Any medical contraindications on the Physical Activity Readiness Questionnaire

          -  Require an assistive device for mobility or has any other condition that may limit or
             prevent participation in moderate-intensity physical activity

          -  Current smoker

          -  Pregnant or planning to become pregnant in the next 6 mos/breastfeeding

          -  Allergy to test substances

          -  Allergy to latex

        Ancillary Study:

          -  Taking metformin

          -  Current medications that could conceivably alter the cardiovascular or
             thermoregulatory control or responses (e.g. beta blockers, calcium channel blockers,
             angiotensin receptor blockers)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David E Conroy, PhD</last_name>
    <phone>814-865-3451</phone>
    <email>conroy@psu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Pennsylvania State University</name>
      <address>
        <city>University Park</city>
        <state>Pennsylvania</state>
        <zip>16802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David E Conroy, PhD</last_name>
      <phone>814-865-3451</phone>
      <email>conroy@psu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Deborah Reese, MS</last_name>
      <phone>814-865-7935</phone>
      <email>dlb43@psu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>David E Conroy</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroprusside</mesh_term>
    <mesh_term>Acetylcholine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT03953326/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

